Monte Rosa Therapeutics’ (GLUE) “Sell (D+)” Rating Reiterated at Weiss Ratings

Weiss Ratings reissued their sell (d+) rating on shares of Monte Rosa Therapeutics (NASDAQ:GLUE) in a report published on Friday morning,Weiss Ratings reports.

Monte Rosa Therapeutics Stock Performance

NASDAQ GLUE opened at $12.85 on Friday. Monte Rosa Therapeutics has a one year low of $3.50 and a one year high of $13.22. The stock has a 50-day moving average of $7.67 and a 200 day moving average of $5.76. The company has a market capitalization of $793.62 million, a price-to-earnings ratio of 35.70 and a beta of 1.61.

Monte Rosa Therapeutics (NASDAQ:GLUE) last released its quarterly earnings data on Thursday, August 7th. The company reported ($0.15) EPS for the quarter, topping the consensus estimate of ($0.31) by $0.16. The company had revenue of $23.19 million during the quarter, compared to the consensus estimate of $7.23 million. Monte Rosa Therapeutics had a return on equity of 9.95% and a net margin of 13.58%. On average, equities analysts predict that Monte Rosa Therapeutics will post -1.49 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Monte Rosa Therapeutics

Several hedge funds have recently bought and sold shares of GLUE. The Manufacturers Life Insurance Company lifted its holdings in shares of Monte Rosa Therapeutics by 2.2% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 119,836 shares of the company’s stock worth $540,000 after buying an additional 2,529 shares during the period. Lazard Asset Management LLC lifted its holdings in shares of Monte Rosa Therapeutics by 42.9% in the 2nd quarter. Lazard Asset Management LLC now owns 10,857 shares of the company’s stock worth $48,000 after buying an additional 3,262 shares during the period. Intech Investment Management LLC lifted its stake in shares of Monte Rosa Therapeutics by 35.4% during the 2nd quarter. Intech Investment Management LLC now owns 29,870 shares of the company’s stock worth $135,000 after purchasing an additional 7,808 shares during the last quarter. Wealth Effects LLC purchased a new stake in shares of Monte Rosa Therapeutics during the 3rd quarter worth $75,000. Finally, Brighton Jones LLC purchased a new stake in shares of Monte Rosa Therapeutics during the 2nd quarter worth $48,000. Institutional investors own 79.96% of the company’s stock.

Monte Rosa Therapeutics Company Profile

Monte Rosa Therapeutics, Inc, a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. The company develops MRT-2359, an orally bioavailable molecular glue degrader targeting the translation termination factor protein GSPT1 for the treatment of MYC-driven tumors; MRT-6160 for the treatment of systemic and central nervous system autoimmune diseases; and MRT-8102 for the treatment of IL-1?/NLRP3 driven inflammatory diseases.